Portal systemic collateral development: Is it a trophic adaptation mechanism to hepatic deprivation?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 11, 2006, Pages 1643-1645

  Aller, Maria Angeles ^a,b   Arias, Jaime ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; NORADRENALIN;

COLLATERAL CIRCULATION; EDITORIAL; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL;

EID: 33748771962     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04508.x     Document Type: Editorial

References (55)

1. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-system collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-94.
2. García-Tsao G. Portal hypertension. Curr. Opin. Gastroenterol. 2002; 18: 351-9.
3. Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol. Clin. North Am. 1992; 21: 1-14.
4. MacMathuna P, Vlavianos P, Westaby D, Williams R. Pathophysiology of portal hypertension. Dig. Dis. 1992; 10(Suppl. 1): 3-15.
5. Bosch J, García-Pagán JC. Complications of cirrhosis I. Portal hypertension. J. Hepatol. 2000; 32(Suppl. 1): 141-56.
6. Chan CC, Chang CC, Huan HC et al. Effects of norepinephrine and acetylcholine on portal-systemic collaterals of common bile duct-ligated cirrhotic rats. J. Gastroenterol. Hepatol. 2005; 20: 1867-72.
7. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am. J. Physiol. 1992; 263: G544-50.
8. Chan CC, Lee FY, Wang SS et al. Effects of vasopressin on portalsystemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999; 30: 630-5.
9. Chan CC, Wang SS, Lee FY et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001; 33: 816-20.
10. Wang SS, Chan CC, Lee FY et al. Effects of long-term octreotide treatment on the response to portal-systemic collaterals to vasopressin in portal hypertensive rats. Eur. J. Clin. Invest. 2002; 32: 316-21.
11. Huang HC, Lee FY, Chan CC et al. Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats. J. Hepatol. 2002; 36: 163-8.
12. Huang HC, Wang SS, Chan CC et al. Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats. J. Hepatol. 2004; 41: 169-70.
13. Chan CC, Wang SS, Lee FY et al. Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats. Eur. J. Clin. Invest. 2004; 34: 290-6.
14. Wattanasiri CS, Gordon FD, Resnick RH. Hyperdynamic circulation in portal hypertension: a comparative model of arterio-venous fistula. Med. Hypotheses 2000; 55: 77-87.
15. Wiest R, Groszmann RS. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin. Liver Dis. 1999; 19: 411-26.
16. Hartleb M, Michielsen PP, Dziiurkowska-Marek A. The role of nitric oxide in portal hypertensive systemic and portal vascular pathology. Acta Gastroenterol. Belg. 1997; 60: 222-32.
17. Shah V. Cellular and molecular basis of portal hypertension. Clin. Liver Dis. 2001; 5: 629-33.
18. Sieber CC, Sumanovski LT, Stumm M, Van der Kooij M, Bathegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J. Hepatol. 2001; 34: 644-50.
19. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of Nω-Nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105: 1464-70.
20. Obert F, Rifflet H, Maiga MY et al. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J. Hepatol. 1997; 26: 167-73.
21. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am. J. Physiol. 1985; 248: G618-25.
22. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J. Hepatol. 1995; 23: 218-24.
23. Fernández M, Bonkovsky HL. Increased heme-oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999; 29: 1672-9.
24. López-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor a: a major contribution to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.
25. Sumanovski LT, Battegay E, Stumm M, Van der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999; 29: 1044-9.
26. Beltowski J, Jamroz A, Borkowska E. Heme-oxygenase and carbon monoxide in the physiology and pathology of the cardiovascular system. Postepy Hig. Med. Dosw. 2004; 3: 83-99.
27. Dmoszynka A, Bojarska-Junak A, Domanski D, Rolinski J, Hus M, Soroka-Wojtaszk O. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk-Lymphoma 2002; 43: 401-6.
28. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation 2002; 105: 2133-5.
29. Jozkowicz A, Huk I, Nigisch A et al. Heme-oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid. Redox Signal. 2003; 5: 155-62.
30. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model. A primary factor for maintenance of chronic portal hypertension. Am. J. Physiol. 1983; 244: G52-7.
31. Newby DE, Mayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal'. Q. J. Med. 2002; 95: 827-30.
32. Paquet K-J. Causes and pathomechanisms of oesophageal varices development. Med. Sci. Monit. 2000; 6: 915-28.
33. Paquet KJ, Kuhn R. Prophylactic endoscopic sclerotherapy in patients with liver cirrhosis and oesophageal varices. Hepatogastroenterology 1997; 44: 625-36.
34. Koshy A, Sekiyama T, Hadengue A, Cerini R, Braillon A, Lebrec D. Effects of alpha 1 and beta-adrenergic antagonists and 5-hydroxytryptamine receptor antagonist on portal-systemic collateral vascular resistance in conscious rats with portal hypertension. J. Gastroenterol. Hepatol. 1992; 7: 449-54.
35. Kojima H, Yamao J, Tsujimoto T, Vemura M, Takaya A, Fukui H. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J. Hepatol. 2000; 32: 43-50.
36. Kojima H, Sakurai S, Kuriyama S et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelium receptor subtype B together with subtype A in vivo. J. Hepatol. 2001; 34: 805-11.
37. Yang YY, Lin HC, Huang YT et al. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J. Hepatol. 2002; 36: 600-6.
38. Lebrec D. Pharmacological treatment of portal hypertension: present and future. J. Hepatol. 1998; 28: 896-907.
39. Bosch J, Abraldes JG, Groszmann RJ. Current management of portal hypertension. J. Hepatol. 2003; 38 (Suppl 1): S54-68.
40. Aller MA, Arias JL, Lorente L, Nava MP, Durán HJ, Arias J. Neuroimmune-endocrine functional pathology system and vascular pathology. Med. Hypotheses 2001; 57: 561-9.
41. Aller MA, Arias JL, Nava MP, Arias J. Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune and endocrine functional systems. Exp. Biol. Med. 2004; 229: 170-81.
42. Kaye EM. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J. Auton. Nerv. Syst. 1998; 72: 210-19.
43. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat using gamma-labelled microspheres. Am. J. Physiol. 1981; 240: G371-5.
44. Benoit JN, Womack WA, Hernández L, Granger DN. 'Forward' and 'backward' flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis. Gastroenterology 1985; 89: 1092-6.
45. Kravetz D, Arderiu MT, Bosch J, Piera C, Setoain J, Rodés J. Increased plasma volume in two models of portal hypertension in the rat: cirrhosis of the liver and partial portal vein ligation. Rev. Esp. Fisiol. 1987; 43: 179-83.
46. Diez-Arias JA, Aller MA, Palma MD et al. Increased duodenal mucosa infiltration by mast cells in the rat with portal hypertension. Dig. Surg. 2001; 18: 34-40.
47. Prieto I, Aller MA, Santamaría L et al. Prehepatic portal hypertension produces increases in mast cell density in the small bowel and in mesenteric lymph nodes in the rat. J. Gastroenterol. Hepatol. 2005; 52: 541-6.
48. Aller MA, Vara E, García C et al. Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. Med. Inflamm. 2005; 9: 101-11.
49. Rozga J, Jeppsson R, Hägerstrand I, Bengmark S. Acute portal vein stenosis. Acta Chir. Scand. 1985; 151: 125-31.
50. Diéguez B, Aller MA, Nava MP et al. Chronic portal hypertension in the rat by triple portal stenosing ligation. J. Invest. Surg. 2002; 15: 329-36.
51. Corcuera MT, Nava MP, Angulo A et al. Splanchnic remodeling secondary to experimental prehepatic portal hypertension. Ann Med. Intern. 2005; 22: 317-22.
52. Alonso MJ, Aller MA, Corcuera MT et al. Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension. Hepatogastroenterology 2005; 52: 541-6.
53. Aller MA, Arias JL, Arias J. Post-traumatic inflammatory response: perhaps a succession of phases with a nutritional purpose. Med. Hypotheses 2004; 63: 42-6.
54. Aller MA, López L, Nava MP, Arias JL, Durán HJ, Arias J. Portal hypertension: return to fetal life to re-attempt differentiation? Med. Hypotheses 2004; 62: 79-81.
55. Dasarathy S, Mullen KD, Conjeevaram HS, Kaminsky-Russ K, Wills LA, McCullough A. Preservation of portal pressure improves growth and metabolic profile in the male portacaval shunted-rat. Dig. Dis. Sci. 2002; 47: 1936-42.